Therapeutic effects of xanthine oxidase inhibitors: Renaissance half a century after the discovery of allopurinol

Pal Pacher, Alex Nivorozhkin, Csaba Szabo

Research output: Contribution to journalArticle

705 Citations (Scopus)

Abstract

The prototypical xanthine oxidase (XO) inhibitor allopurinol, has been the cornerstone of the clinical management of gout and conditions associated with hyperuricemia for several decades. More recent data indicate that XO also plays an important role in various forms of ischemic and other types of tissue and vascular injuries, inflammatory diseases, and chronic heart failure. Allopurinol and its active metabolite oxypurinol showed considerable promise in the treatment of these conditions both in experimental animals and in small-scale human clinical trials. Although some of the beneficial effects of these compounds may be unrelated to the inhibition of the XO, the encouraging findings rekindled significant interest in the development of additional, novel series of XO inhibitors for various therapeutic indications. Here we present a critical overview of the effects of XO inhibitors in various pathophysiological conditions and also review the various emerging therapeutic strategies offered by this approach.

Original languageEnglish (US)
Pages (from-to)87-114
Number of pages28
JournalPharmacological Reviews
Volume58
Issue number1
DOIs
StatePublished - Mar 2006
Externally publishedYes

Fingerprint

Allopurinol
Xanthine Oxidase
Therapeutic Uses
Oxypurinol
Hyperuricemia
Gout
Vascular System Injuries
Chronic Disease
Heart Failure
Renaissance
Clinical Trials
Therapeutics

ASJC Scopus subject areas

  • Pharmacology

Cite this

Therapeutic effects of xanthine oxidase inhibitors : Renaissance half a century after the discovery of allopurinol. / Pacher, Pal; Nivorozhkin, Alex; Szabo, Csaba.

In: Pharmacological Reviews, Vol. 58, No. 1, 03.2006, p. 87-114.

Research output: Contribution to journalArticle

Pacher, Pal ; Nivorozhkin, Alex ; Szabo, Csaba. / Therapeutic effects of xanthine oxidase inhibitors : Renaissance half a century after the discovery of allopurinol. In: Pharmacological Reviews. 2006 ; Vol. 58, No. 1. pp. 87-114.
@article{c0de34db259a4780993e0ed076286191,
title = "Therapeutic effects of xanthine oxidase inhibitors: Renaissance half a century after the discovery of allopurinol",
abstract = "The prototypical xanthine oxidase (XO) inhibitor allopurinol, has been the cornerstone of the clinical management of gout and conditions associated with hyperuricemia for several decades. More recent data indicate that XO also plays an important role in various forms of ischemic and other types of tissue and vascular injuries, inflammatory diseases, and chronic heart failure. Allopurinol and its active metabolite oxypurinol showed considerable promise in the treatment of these conditions both in experimental animals and in small-scale human clinical trials. Although some of the beneficial effects of these compounds may be unrelated to the inhibition of the XO, the encouraging findings rekindled significant interest in the development of additional, novel series of XO inhibitors for various therapeutic indications. Here we present a critical overview of the effects of XO inhibitors in various pathophysiological conditions and also review the various emerging therapeutic strategies offered by this approach.",
author = "Pal Pacher and Alex Nivorozhkin and Csaba Szabo",
year = "2006",
month = "3",
doi = "10.1124/pr.58.1.6",
language = "English (US)",
volume = "58",
pages = "87--114",
journal = "Pharmacological Reviews",
issn = "0031-6997",
publisher = "American Society for Pharmacology and Experimental Therapeutics",
number = "1",

}

TY - JOUR

T1 - Therapeutic effects of xanthine oxidase inhibitors

T2 - Renaissance half a century after the discovery of allopurinol

AU - Pacher, Pal

AU - Nivorozhkin, Alex

AU - Szabo, Csaba

PY - 2006/3

Y1 - 2006/3

N2 - The prototypical xanthine oxidase (XO) inhibitor allopurinol, has been the cornerstone of the clinical management of gout and conditions associated with hyperuricemia for several decades. More recent data indicate that XO also plays an important role in various forms of ischemic and other types of tissue and vascular injuries, inflammatory diseases, and chronic heart failure. Allopurinol and its active metabolite oxypurinol showed considerable promise in the treatment of these conditions both in experimental animals and in small-scale human clinical trials. Although some of the beneficial effects of these compounds may be unrelated to the inhibition of the XO, the encouraging findings rekindled significant interest in the development of additional, novel series of XO inhibitors for various therapeutic indications. Here we present a critical overview of the effects of XO inhibitors in various pathophysiological conditions and also review the various emerging therapeutic strategies offered by this approach.

AB - The prototypical xanthine oxidase (XO) inhibitor allopurinol, has been the cornerstone of the clinical management of gout and conditions associated with hyperuricemia for several decades. More recent data indicate that XO also plays an important role in various forms of ischemic and other types of tissue and vascular injuries, inflammatory diseases, and chronic heart failure. Allopurinol and its active metabolite oxypurinol showed considerable promise in the treatment of these conditions both in experimental animals and in small-scale human clinical trials. Although some of the beneficial effects of these compounds may be unrelated to the inhibition of the XO, the encouraging findings rekindled significant interest in the development of additional, novel series of XO inhibitors for various therapeutic indications. Here we present a critical overview of the effects of XO inhibitors in various pathophysiological conditions and also review the various emerging therapeutic strategies offered by this approach.

UR - http://www.scopus.com/inward/record.url?scp=33644631485&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33644631485&partnerID=8YFLogxK

U2 - 10.1124/pr.58.1.6

DO - 10.1124/pr.58.1.6

M3 - Article

C2 - 16507884

AN - SCOPUS:33644631485

VL - 58

SP - 87

EP - 114

JO - Pharmacological Reviews

JF - Pharmacological Reviews

SN - 0031-6997

IS - 1

ER -